Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04188665 · ClinicalTrials.gov registry record · Early Phase 1
Using MASL to Combat Oral Cancer
A Early Phase 1 study, sponsored by Rowan University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT04188665 is a Early Phase 1 study that has completed, run by Rowan University. The registered enrollment target is 18 participants.
The verdict
NCT04188665, a Early Phase 1 study, has completed, sponsored by Rowan University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This project will evaluate the expression of a receptor called podoplanin (PDPN) in cells from oral cancers and precancerous lesions. We will also determine how sensitive oral cancer cells are to a potential drug called Maackia amurensis seed lectin (MASL).
Interventions
- OTHER Placebo
- DRUG MASL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-01-29 |
| Est. Completion | 2025-05-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04188665
The ClinicalTrials.gov registry entry for NCT04188665 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rowan University, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04188665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04188665 about?
NCT04188665 is a clinical study titled "Using MASL to Combat Oral Cancer". This project will evaluate the expression of a receptor called podoplanin (PDPN) in cells from oral cancers and precancerous lesions. We will also determine how sensitive oral cancer cells are to a potential drug called Maackia amurensis seed lectin (MASL).
What is the current status of trial NCT04188665?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2021-01-29. Estimated completion is 2025-05-15.
What interventions are being tested in trial NCT04188665?
The interventions under investigation include: Placebo (OTHER), MASL (DRUG).
Who is sponsoring clinical trial NCT04188665?
This trial is sponsored by Rowan University, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.